Kidswell Bio Corporation (4584.T)
JPY 102.0
(-7.27%)
JPY 102.0
(-7.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.25 Billion JPY | 59.85% |
| 2022 | 2.66 Billion JPY | 50.57% |
| 2021 | 1.76 Billion JPY | -23.93% |
| 2020 | 2.32 Billion JPY | 10.4% |
| 2019 | 2.1 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.89 Billion JPY | -8.43% |
| 2023 Q1 | 2.27 Billion JPY | -14.49% |
| 2023 Q4 | 4.25 Billion JPY | 13.29% |
| 2023 Q3 | 3.75 Billion JPY | 77.23% |
| 2023 Q2 | 2.11 Billion JPY | -6.89% |
| 2023 FY | 4.25 Billion JPY | 59.85% |
| 2022 Q2 | 2.56 Billion JPY | 0.0% |
| 2022 FY | 2.66 Billion JPY | 50.57% |
| 2022 Q4 | 2.66 Billion JPY | 266125900.0% |
| 2022 Q3 | 1000.00 JPY | -100.0% |
| 2021 FY | 1.76 Billion JPY | -23.93% |
| 2020 FY | 2.32 Billion JPY | 10.4% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | -31.018% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -6608.735% |
| GNI Group Ltd. | 26.34 Billion JPY | 83.85% |
| Linical Co., Ltd. | 10.3 Billion JPY | 58.718% |
| Trans Genic Inc. | 3.81 Billion JPY | -11.581% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -620.781% |
| Soiken Holdings Inc. | 697.02 Million JPY | -510.321% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | -40.829% |
| AnGes, Inc. | 2.78 Billion JPY | -52.51% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -728.275% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 95.294% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -1104.196% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -157.84% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -800.61% |
| CanBas Co., Ltd. | 91.98 Million JPY | -4524.599% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -288.995% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -425.305% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -616.499% |
| PeptiDream Inc. | 29.11 Billion JPY | 85.388% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -650.94% |
| Ribomic Inc. | 155.8 Million JPY | -2630.315% |
| SanBio Company Limited | 2.25 Billion JPY | -88.66% |
| Healios K.K. | 11.28 Billion JPY | 62.307% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -1593.037% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -1052.866% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -1661.544% |
| StemRIM | 187 Million JPY | -2174.907% |
| CellSource Co., Ltd. | 677.73 Million JPY | -527.686% |
| FunPep Company Limited | 189.32 Million JPY | -2146.982% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -612.629% |
| Stella Pharma Corporation | 1.44 Billion JPY | -194.683% |
| TMS Co., Ltd. | 97.68 Million JPY | -4254.713% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -4549.568% |
| Cuorips Inc. | 200.96 Million JPY | -2016.866% |
| K Pharma,Inc. | 209.13 Million JPY | -1934.139% |
| Takara Bio Inc. | 11.42 Billion JPY | 62.749% |
| ReproCELL Incorporated | 741.03 Million JPY | -474.075% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -363.552% |
| StemCell Institute Inc. | 3.85 Billion JPY | -10.482% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -368.288% |
| CellSeed Inc. | 301.04 Million JPY | -1313.094% |